Becenun

• Antineoplastic Agents
• ATC:L01AD01

• BCNU
• Becenun
• Bi CNU
• Bicnu
• Bischlorethylnitrosourea
• Bischlorethylnitrosurea
• Carmubris
• Carmustin
• Gliadel
• Gliadel Wafer
• Nitrumon

• No information avaliable

C₅H₉Cl₂N₃O₂

http://www.rxlist.com/cgi/generic3/carmustine.htm

http://www.accessdata.fda.gov/scripts/cder/onctools/labels.cfm?GN=carmustine

Becenun MSDS

Johnston TP et al. J Med Chem 122:669-681(1963).

214.049 g/mol

31 ^oC

< 0.1 g/100 mL at 18 °C

Solid

1.256

Powder for solution; Wafer

For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.

Carmustine is one of the nitrosoureas indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in treatment of brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas. Although it is generally agreed that carmustine alkylates DNA and RNA, it is not cross resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins.

5 to 28% bioavailability

The oral LD₅₀s in rat and mouse are 20 mg/kg and 45 mg/kg, respectively. Side effects include leukopenia, thrombocytopenia, nausea. Toxic effects include pulmonary fibrosis (20-0%) and bone marrow toxicity.

No information avaliable

Humans and other mammals